For example, the Tim-3/Gal-9 and TIGIT negative checkpoint receptor pathways are implicated in GvHD severity, and we have previously shown macaque cross-reactivity for human-specific reagents targeting these pathways27–30. This evidence concerns the gene LGALS9 and graft versus host disease.